<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Wilsons Disease <-> Osteoporosis - Comorbidity</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        a {
            color: var(--primary-dark);
            text-decoration: none;
        }

        a:hover {
            text-decoration: underline;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.1rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-subtitle {
            margin-top: 12px;
            color: rgba(255,255,255,0.85);
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
            font-weight: 700;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-accent {
            background: #ede9fe;
            color: #5b21b6;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-weight: 600;
            margin-bottom: 4px;
        }

        .mapping-notes {
            font-size: 0.9rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .field {
            margin-top: 6px;
        }

        .field-label {
            font-weight: 600;
            margin-right: 6px;
        }

        .metrics {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 10px;
            margin-top: 8px;
        }

        .metric {
            background: var(--bg);
            border: 1px solid var(--border);
            border-radius: 10px;
            padding: 8px 10px;
            font-size: 0.9rem;
        }

        .evidence {
            margin-top: 8px;
        }

        .evidence-item {
            border-left: 3px solid #94a3b8;
            padding-left: 10px;
            margin: 8px 0;
            color: var(--text-muted);
        }

        .evidence-item strong {
            color: var(--text);
        }

        .go-terms {
            margin: 8px 0 0;
            padding-left: 18px;
        }

        details {
            margin-top: 12px;
        }

        pre {
            background: #0f172a;
            color: #e2e8f0;
            padding: 12px;
            border-radius: 10px;
            overflow-x: auto;
            font-size: 0.85rem;
        }

        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        @media (max-width: 720px) {
            .page-header {
                padding: 28px 20px;
            }

            .page-header h1 {
                font-size: 1.7rem;
            }

            .section-grid {
                grid-template-columns: 1fr;
            }
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Comorbidity</span>
        </nav>

        <header class="page-header">
            <h1>Wilsons Disease <-> Osteoporosis</h1>
            <div class="header-meta">
                <span class="badge badge-category">Comorbidity</span>
                
                <span class="badge badge-mondo">UNKNOWN</span>
                
                
                <span class="badge badge-category">CANDIDATE</span>
                
            </div>
            
            <div class="header-subtitle">Candidate literature-backed comorbidity linking Wilson disease to reduced bone health and osteoporosis. Most available evidence is prevalence-focused (cross-sectional or pooled prevalence), so temporal directionality remains incompletely established despite biologic plausibility of Wilson disease preceding bone loss.</div>
            
        </header>

        <div class="section-grid">
            <div class="card">
                <div class="card-header">
                    <div class="card-icon" style="background: #e0f2fe; color: #0369a1;">A</div>
                    <h2 class="card-title">Disease A</h2>
                </div>
                <div class="mapping-title">
                    
                    <a href="../disorders/Wilsons_Disease.html">Wilsons Disease</a>
                    
                </div>
                
                <div class="field"><span class="field-label">Slug:</span>Wilsons_Disease</div>
                
                
                
            </div>
            <div class="card">
                <div class="card-header">
                    <div class="card-icon" style="background: #ede9fe; color: #6d28d9;">B</div>
                    <h2 class="card-title">Disease B</h2>
                </div>
                <div class="mapping-title">
                    
                    <a href="../disorders/Osteoporosis.html">Osteoporosis</a>
                    
                </div>
                
                <div class="field"><span class="field-label">Slug:</span>Osteoporosis</div>
                
                
                
            </div>
        </div>

        

        
        <div class="card" id="signals">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">S</div>
                <h2 class="card-title">Association Signals</h2>
            </div>
            <div class="mapping-section">
                
                <div class="mapping-item">
                    <div class="mapping-title">Signal 1</div>
                    <div class="tag-list" style="margin-bottom: 8px;">
                        <span class="tag tag-parent">COHD</span>
                        <span class="tag tag-classification">EHR_COHORT_ASSOCIATION</span>
                        <span class="tag tag-mechanistic">UNKNOWN</span>
                    </div>
                    <div class="field"><span class="field-label">Population:</span>COHD dataset_id=3 (5-year hierarchical), patient-level co-occurrence in Columbia University Irving Medical Center OMOP data.</div>
                    
                    
                    <div class="field"><span class="field-label">Signal IDs:</span>
                        
                        <a href="https://bioregistry.io/OMOP:436672" target="_blank">OMOP:436672</a>
                        
                        
                         -> 
                        <a href="https://bioregistry.io/OMOP:80502" target="_blank">OMOP:80502</a>
                        
                    </div>
                    
                    
                    <div class="mapping-notes"><span class="field-label">Mapping notes:</span>Wilson disease did not return a directly observed COHD concept in this dataset search. As a proxy, disorder A uses OMOP concept 436672 (SNOMED:79886009, &#34;Disorder of copper metabolism&#34;), which can include Wilson disease and related copper disorders in hierarchical counts. Disorder B uses OMOP concept 80502 (SNOMED:64859006, &#34;Osteoporosis&#34;).</div>
                    
                    
                    <div class="field"><span class="field-label">Temporal:</span>
                        A before B: 
                        , B before A: 
                        , Same time: 
                    </div>
                    

                    
                    
                    <div class="metrics">
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.00020603384841795438</div>
                            
                            <div>CI: 2.9026733621665555e-05 - 0.0004477478284230321</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Relative frequency of osteoporosis among disorder-of-copper-metabolism patients in COHD.</div>
                        </div>
                        
                        <div class="metric">
                            <div><strong>LOG_OBS_EXP_RATIO</strong>: 0.7532713092329928</div>
                            
                            <div>CI: -1.1926388398223207 - 1.6405745042338955</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Natural-log observed/expected co-occurrence ratio from COHD obsExpRatio endpoint.</div>
                        </div>
                        
                        <div class="metric">
                            <div><strong>CHI_SQUARE</strong>: 4.247044751791994</div>
                            
                            <div>CI:  - </div>
                            
                            <div>p: 0.03931869490225846</div>
                            <div>FDR: 1.0</div>
                            <div>Chi-square association statistic from COHD; adjusted p-value from endpoint. Note FDR=1.0 — does not survive multiple-testing correction.</div>
                        </div>
                        
                    </div>
                    

                    
                    

                    
                </div>
                
                <div class="mapping-item">
                    <div class="mapping-title">Signal 2</div>
                    <div class="tag-list" style="margin-bottom: 8px;">
                        <span class="tag tag-parent">LITERATURE</span>
                        <span class="tag tag-classification">LITERATURE_ASSOCIATION</span>
                        <span class="tag tag-mechanistic">UNKNOWN</span>
                    </div>
                    <div class="field"><span class="field-label">Population:</span>Systematic review/meta-analysis of 4 studies (n=283 Wilson disease patients).</div>
                    
                    
                    
                    
                    <div class="field"><span class="field-label">Temporal:</span>
                        A before B: 
                        , B before A: 
                        , Same time: 
                    </div>
                    

                    
                    
                    <div class="metrics">
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.365</div>
                            
                            <div>CI: 0.148 - 0.657</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Pooled prevalence of osteopenia in Wilson disease.</div>
                        </div>
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.277</div>
                            
                            <div>CI: 0.086 - 0.609</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Pooled prevalence of osteoporosis in Wilson disease.</div>
                        </div>
                        
                    </div>
                    

                    
                    
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/29110062" target="_blank">PMID:29110062</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5%"</div>
            
            
            <div>Meta-analysis reports substantial pooled prevalence of both osteopenia and osteoporosis in Wilson disease cohorts.</div>
            
        </div>
        
    </div>
    
    
                    
                    

                    
                </div>
                
                <div class="mapping-item">
                    <div class="mapping-title">Signal 3</div>
                    <div class="tag-list" style="margin-bottom: 8px;">
                        <span class="tag tag-parent">LITERATURE</span>
                        <span class="tag tag-classification">LITERATURE_ASSOCIATION</span>
                        <span class="tag tag-mechanistic">UNKNOWN</span>
                    </div>
                    <div class="field"><span class="field-label">Population:</span>Adult-only subgroup from meta-analysis of Wilson disease studies.</div>
                    
                    
                    
                    
                    <div class="field"><span class="field-label">Temporal:</span>
                        A before B: 
                        , B before A: 
                        , Same time: 
                    </div>
                    

                    
                    
                    <div class="metrics">
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.176</div>
                            
                            <div>CI: 0.067 - 0.386</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Estimated adult prevalence of osteoporosis in Wilson disease.</div>
                        </div>
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.0801</div>
                            
                            <div>CI: 0.0405 - 0.152</div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Estimated adult prevalence of vertebral fracture in Wilson disease.</div>
                        </div>
                        
                    </div>
                    

                    
                    
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/29110062" target="_blank">PMID:29110062</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"When meta-analysis was limited only to adults, the estimated prevalence rates of osteopenia, osteoporosis, and vertebral fracture were 50.0% (95%CI: 42.0%-58.0%), 17.6% (95%CI: 6.7%-38.6%) and 8.01% (95%CI: 4.05%-15.2%), respectively."</div>
            
            
            <div>Adult-only pooled data support clinically relevant osteoporosis and fracture burden in Wilson disease.</div>
            
        </div>
        
    </div>
    
    
                    
                    

                    
                </div>
                
                <div class="mapping-item">
                    <div class="mapping-title">Signal 4</div>
                    <div class="tag-list" style="margin-bottom: 8px;">
                        <span class="tag tag-parent">LITERATURE</span>
                        <span class="tag tag-classification">LITERATURE_ASSOCIATION</span>
                        <span class="tag tag-mechanistic">UNKNOWN</span>
                    </div>
                    <div class="field"><span class="field-label">Population:</span>Pediatric cross-sectional Wilson disease cohort (n=15) with DEXA assessment.</div>
                    
                    
                    
                    
                    <div class="field"><span class="field-label">Temporal:</span>
                        A before B: 
                        , B before A: 
                        , Same time: 
                    </div>
                    

                    
                    
                    <div class="metrics">
                        
                        <div class="metric">
                            <div><strong>PREVALENCE</strong>: 0.2</div>
                            
                            <div>CI:  - </div>
                            
                            <div>p: </div>
                            <div>FDR: </div>
                            <div>Osteoporosis prevalence in pediatric Wilson disease cohort.</div>
                        </div>
                        
                    </div>
                    

                    
                    
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/40950651" target="_blank">PMID:40950651</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"DEXA revealed bone disease in 60%: mild osteopenia (13%), moderate (27%), and osteoporosis (20%)."</div>
            
            
            <div>Pediatric cohort indicates early bone involvement including osteoporosis in Wilson disease.</div>
            
        </div>
        
    </div>
    
    
                    
                    

                    
                </div>
                
            </div>
        </div>
        

        
        <div class="card" id="hypotheses">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #1e40af;">H</div>
                <h2 class="card-title">Hypotheses</h2>
            </div>
            
            <div class="mapping-item">
                <div class="field">Hypothesis: copper-related multisystem toxicity in Wilson disease affects both bone and renal tissues, creating a bone fragility milieu.</div>
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/38731973" target="_blank">PMID:38731973</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: OTHER</div>
            
            
            <div>"This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones"</div>
            
            
            <div>Review summary supports direct involvement of both kidney and bone tissues in Wilson disease.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/38731973" target="_blank">PMID:38731973</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: OTHER</div>
            
            
            <div>"Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia."</div>
            
            
            <div>Renal tubular dysfunction and osteoporosis are co-listed clinical features, supporting a linked mineral-handling hypothesis.</div>
            
        </div>
        
    </div>
    
    
                
                <div class="field"><span class="field-label">Pathophysiology:</span></div>
                
                <div class="field">
                    <strong>Copper toxicity with renal-bone interaction</strong>: Copper toxicity in Wilson disease may simultaneously injure renal tubular and skeletal compartments, predisposing to mineral dysregulation and bone fragility.
                </div>
                
                
                <div class="field">
                    <span class="field-label">Biological processes:</span>
                    <div class="tag-list">
                        
                        
                        <span class="tag tag-classification">
                            <a href="http://purl.obolibrary.org/obo/GO_0046849" target="_blank">bone remodeling</a>
                        </span>
                        
                        
                    </div>
                </div>
                
                
                
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/38731973" target="_blank">PMID:38731973</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: OTHER</div>
            
            
            <div>"This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones"</div>
            
            
            <div>Supports multi-organ copper injury including kidney and bone.</div>
            
        </div>
        
    </div>
    
    
                
                
                
            </div>
            
            <div class="mapping-item">
                <div class="field">Hypothesis: hepatic synthetic and nutritional status contributes to bone health variability in Wilson disease.</div>
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/40950651" target="_blank">PMID:40950651</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"However, serum albumin positively correlated with bone density (P = .018)."</div>
            
            
            <div>Albumin-bone density correlation supports a liver function and nutritional mechanism affecting bone status.</div>
            
        </div>
        
    </div>
    
    
                
                <div class="field"><span class="field-label">Pathophysiology:</span></div>
                
                <div class="field">
                    <strong>Albumin-linked bone vulnerability</strong>: Lower albumin in Wilson disease may reflect hepatic dysfunction and/or nutritional compromise associated with poorer bone mineralization.
                </div>
                
                
                
                
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/40950651" target="_blank">PMID:40950651</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"Bone disease is frequent and often subclinical in pediatric Wilson&#39;s disease."</div>
            
            
            <div>Supports frequent, clinically subtle bone involvement in Wilson disease.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/40950651" target="_blank">PMID:40950651</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"However, serum albumin positively correlated with bone density (P = .018)."</div>
            
            
            <div>Correlative evidence links albumin and bone density in pediatric Wilson disease.</div>
            
        </div>
        
    </div>
    
    
                
                
                
            </div>
            
            <div class="mapping-item">
                <div class="field">Hypothesis: host factors (age and sex) modify osteoporosis risk expression in Wilson disease.</div>
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/29110062" target="_blank">PMID:29110062</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"Meta-regressionshowed significant impacts of age (negative correlation; P=0.002) and male status (positive correlation;P &lt; 0.001) on the prevalence of osteoporosis."</div>
            
            
            <div>Meta-regression indicates age/sex interaction with osteoporosis prevalence, suggesting biologic risk modifiers.</div>
            
        </div>
        
    </div>
    
    
                
                <div class="field"><span class="field-label">Pathophysiology:</span></div>
                
                <div class="field">
                    <strong>Age-sex risk modulation</strong>: Osteoporosis risk in Wilson disease appears modified by demographic and host factors, implying interaction between copper-related pathology and baseline bone-risk biology.
                </div>
                
                
                
                
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/29110062" target="_blank">PMID:29110062</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"Meta-regressionshowed significant impacts of age (negative correlation; P=0.002) and male status (positive correlation;P &lt; 0.001) on the prevalence of osteoporosis."</div>
            
            
            <div>Quantifies host-factor dependence of osteoporosis prevalence in Wilson disease cohorts.</div>
            
        </div>
        
    </div>
    
    
                
                
                
            </div>
            
            <div class="mapping-item">
                <div class="field">Hypothesis: treatment-course instability (adherence barriers and therapy-associated neurologic worsening) may mediate osteoporosis risk in Wilson disease through reduced mobility and disease-control disruption.</div>
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/37116715" target="_blank">PMID:37116715</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"In this study, we identified two peaks in NW: an early (≤3 months) treatment-associated peak and a late (&gt;12 months of treatment) adherence-associated peak."</div>
            
            
            <div>Large multicenter cohort links treatment phase and adherence status to neurological destabilization.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/35887738" target="_blank">PMID:35887738</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"As adherence to treatment is a key factor in the successful management of WD, physicians need to be even more vigilant in detecting adherence difficulties in patients receiving treatment with TETA 2HCL."</div>
            
            
            <div>Identifies adherence as a key determinant of Wilson disease control.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/40950651" target="_blank">PMID:40950651</a></strong>
                
                 (PARTIAL)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"Larger studies are needed to evaluate the effects of treatment and micronutrient status on bone health."</div>
            
            
            <div>Pediatric bone-density study explicitly flags treatment and micronutrient status as potential bone-health determinants requiring deeper study.</div>
            
        </div>
        
    </div>
    
    
                
                <div class="field"><span class="field-label">Pathophysiology:</span></div>
                
                <div class="field">
                    <strong>Treatment-course instability and disuse-bone pathway</strong>: In some Wilson disease patients, inadequate decoppering control from adherence barriers or treatment-phase neurologic worsening may increase functional dependency, reduce skeletal loading, and contribute to bone loss and fracture risk.
                </div>
                
                
                
                
                
    
    <div class="evidence">
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/32398357" target="_blank">PMID:32398357</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"All were highly dependent before LT (median mRS score 5)."</div>
            
            
            <div>Refractory neurologic Wilson disease can produce profound dependency consistent with reduced mechanical loading.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/32398357" target="_blank">PMID:32398357</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"LT is a rescue therapeutic option that should be carefully discussed in selected patients with neurologic WD resistant to anticopper therapies (chelators or zinc salts) as it might allow patients to gain physical independency with a reasonable risk."</div>
            
            
            <div>Improvement in physical independence after rescue therapy supports a disability-mediated intermediate mechanism.</div>
            
        </div>
        
        <div class="evidence-item">
            <div>
                
                <strong><a href="http://www.ncbi.nlm.nih.gov/pubmed/29110062" target="_blank">PMID:29110062</a></strong>
                
                 (SUPPORT)
            </div>
            
            <div>Source: HUMAN_CLINICAL</div>
            
            
            <div>"When meta-analysis was limited only to adults, the estimated prevalence rates of osteopenia, osteoporosis, and vertebral fracture were 50.0% (95%CI: 42.0%-58.0%), 17.6% (95%CI: 6.7%-38.6%) and 8.01% (95%CI: 4.05%-15.2%), respectively."</div>
            
            
            <div>Adult Wilson disease cohorts show clinically meaningful osteoporosis and vertebral fracture burden.</div>
            
        </div>
        
    </div>
    
    
                
                
                
            </div>
            
        </div>
        

        

        

        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e2e8f0; color: #334155;">Y</div>
                <h2 class="card-title">Raw YAML</h2>
            </div>
            <details>
                <summary>Show YAML</summary>
                <pre>name: com_Wilsons_Disease__Osteoporosis
creation_date: &#39;2026-02-20T00:00:00Z&#39;
updated_date: &#39;2026-02-20T00:00:00Z&#39;
curation_status: CANDIDATE
notes: &gt;-
  Candidate literature-backed comorbidity linking Wilson disease to reduced bone
  health and osteoporosis. Most available evidence is prevalence-focused
  (cross-sectional or pooled prevalence), so temporal directionality remains
  incompletely established despite biologic plausibility of Wilson disease
  preceding bone loss.

disease_a:
  slug: Wilsons_Disease
  preferred_term: Wilson disease
  term:
    id: MONDO:0010200
    label: Wilson disease

disease_b:
  slug: Osteoporosis
  preferred_term: osteoporosis
  term:
    id: MONDO:0005298
    label: osteoporosis

directionality: UNKNOWN

hypotheses:
- description: &gt;-
    Hypothesis: copper-related multisystem toxicity in Wilson disease affects
    both bone and renal tissues, creating a bone fragility milieu.
  evidence:
  - reference: PMID:38731973
    supports: SUPPORT
    evidence_source: OTHER
    snippet: &#34;This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones&#34;
    explanation: Review summary supports direct involvement of both kidney and bone tissues in Wilson disease.
  - reference: PMID:38731973
    supports: SUPPORT
    evidence_source: OTHER
    snippet: &#34;Among these are depression, psychosis, dysarthria, ataxia, writing problems, dysphagia, renal tubular dysfunction, Kayser-Fleischer corneal rings, cardiomyopathy, cardiac arrhythmias, rhabdomyolysis, osteoporosis, osteomalacia, arthritis, and arthralgia.&#34;
    explanation: Renal tubular dysfunction and osteoporosis are co-listed clinical features, supporting a linked mineral-handling hypothesis.
  pathophysiology:
  - name: Copper toxicity with renal-bone interaction
    description: &gt;-
      Copper toxicity in Wilson disease may simultaneously injure renal tubular
      and skeletal compartments, predisposing to mineral dysregulation and bone
      fragility.
    biological_processes:
    - preferred_term: bone remodeling
      term:
        id: GO:0046849
        label: bone remodeling
    evidence:
    - reference: PMID:38731973
      supports: SUPPORT
      evidence_source: OTHER
      snippet: &#34;This explains why copper injures not only the liver, but also the brain, kidneys, eyes, heart, muscles, and bones&#34;
      explanation: Supports multi-organ copper injury including kidney and bone.
- description: &gt;-
    Hypothesis: hepatic synthetic and nutritional status contributes to bone
    health variability in Wilson disease.
  evidence:
  - reference: PMID:40950651
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;However, serum albumin positively correlated with bone density (P = .018).&#34;
    explanation: Albumin-bone density correlation supports a liver function and nutritional mechanism affecting bone status.
  pathophysiology:
  - name: Albumin-linked bone vulnerability
    description: &gt;-
      Lower albumin in Wilson disease may reflect hepatic dysfunction and/or
      nutritional compromise associated with poorer bone mineralization.
    evidence:
    - reference: PMID:40950651
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;Bone disease is frequent and often subclinical in pediatric Wilson&#39;s disease.&#34;
      explanation: Supports frequent, clinically subtle bone involvement in Wilson disease.
    - reference: PMID:40950651
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;However, serum albumin positively correlated with bone density (P = .018).&#34;
      explanation: Correlative evidence links albumin and bone density in pediatric Wilson disease.
- description: &gt;-
    Hypothesis: host factors (age and sex) modify osteoporosis risk expression
    in Wilson disease.
  evidence:
  - reference: PMID:29110062
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Meta-regressionshowed significant impacts of age (negative correlation; P=0.002) and male status (positive correlation;P &lt; 0.001) on the prevalence of osteoporosis.&#34;
    explanation: Meta-regression indicates age/sex interaction with osteoporosis prevalence, suggesting biologic risk modifiers.
  pathophysiology:
  - name: Age-sex risk modulation
    description: &gt;-
      Osteoporosis risk in Wilson disease appears modified by demographic and
      host factors, implying interaction between copper-related pathology and
      baseline bone-risk biology.
    evidence:
    - reference: PMID:29110062
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;Meta-regressionshowed significant impacts of age (negative correlation; P=0.002) and male status (positive correlation;P &lt; 0.001) on the prevalence of osteoporosis.&#34;
      explanation: Quantifies host-factor dependence of osteoporosis prevalence in Wilson disease cohorts.
- description: &gt;-
    Hypothesis: treatment-course instability (adherence barriers and
    therapy-associated neurologic worsening) may mediate osteoporosis risk in
    Wilson disease through reduced mobility and disease-control disruption.
  evidence:
  - reference: PMID:37116715
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;In this study, we identified two peaks in NW: an early (≤3 months) treatment-associated peak and a late (&gt;12 months of treatment) adherence-associated peak.&#34;
    explanation: Large multicenter cohort links treatment phase and adherence status to neurological destabilization.
  - reference: PMID:35887738
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;As adherence to treatment is a key factor in the successful management of WD, physicians need to be even more vigilant in detecting adherence difficulties in patients receiving treatment with TETA 2HCL.&#34;
    explanation: Identifies adherence as a key determinant of Wilson disease control.
  - reference: PMID:40950651
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Larger studies are needed to evaluate the effects of treatment and micronutrient status on bone health.&#34;
    explanation: Pediatric bone-density study explicitly flags treatment and micronutrient status as potential bone-health determinants requiring deeper study.
  pathophysiology:
  - name: Treatment-course instability and disuse-bone pathway
    description: &gt;-
      In some Wilson disease patients, inadequate decoppering control from
      adherence barriers or treatment-phase neurologic worsening may increase
      functional dependency, reduce skeletal loading, and contribute to bone
      loss and fracture risk.
    evidence:
    - reference: PMID:32398357
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;All were highly dependent before LT (median mRS score 5).&#34;
      explanation: Refractory neurologic Wilson disease can produce profound dependency consistent with reduced mechanical loading.
    - reference: PMID:32398357
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;LT is a rescue therapeutic option that should be carefully discussed in selected patients with neurologic WD resistant to anticopper therapies (chelators or zinc salts) as it might allow patients to gain physical independency with a reasonable risk.&#34;
      explanation: Improvement in physical independence after rescue therapy supports a disability-mediated intermediate mechanism.
    - reference: PMID:29110062
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;When meta-analysis was limited only to adults, the estimated prevalence rates of osteopenia, osteoporosis, and vertebral fracture were 50.0% (95%CI: 42.0%-58.0%), 17.6% (95%CI: 6.7%-38.6%) and 8.01% (95%CI: 4.05%-15.2%), respectively.&#34;
      explanation: Adult Wilson disease cohorts show clinically meaningful osteoporosis and vertebral fracture burden.

association_signals:
- source: COHD
  method: EHR_COHORT_ASSOCIATION
  signal_disorder_a_id: OMOP:436672
  signal_disorder_b_id: OMOP:80502
  population: &gt;-
    COHD dataset_id=3 (5-year hierarchical), patient-level co-occurrence in
    Columbia University Irving Medical Center OMOP data.
  mapping_notes: &gt;-
    Wilson disease did not return a directly observed COHD concept in this
    dataset search. As a proxy, disorder A uses OMOP concept 436672
    (SNOMED:79886009, &#34;Disorder of copper metabolism&#34;), which can include Wilson
    disease and related copper disorders in hierarchical counts. Disorder B uses
    OMOP concept 80502 (SNOMED:64859006, &#34;Osteoporosis&#34;).
  disorder_a_count: 168
  disorder_b_count: 33975
  pair_count: 7
  limited_precision: true
  precision_count_threshold: 10
  directionality: UNKNOWN
  statistics:
    metrics:
    - metric_type: PREVALENCE
      metric_value: 0.00020603384841795438
      metric_ci_lower: 0.000029026733621665555
      metric_ci_upper: 0.0004477478284230321
      notes: Relative frequency of osteoporosis among disorder-of-copper-metabolism patients in COHD.
    - metric_type: LOG_OBS_EXP_RATIO
      metric_value: 0.7532713092329928
      metric_ci_lower: -1.1926388398223207
      metric_ci_upper: 1.6405745042338955
      notes: Natural-log observed/expected co-occurrence ratio from COHD obsExpRatio endpoint.
    - metric_type: CHI_SQUARE
      metric_value: 4.247044751791994
      p_value: 0.03931869490225846
      fdr: 1.0
      notes: Chi-square association statistic from COHD; adjusted p-value from endpoint. Note FDR=1.0 — does not survive multiple-testing correction.
  notes: Supportive but weak COHD EHR association signal; chi-square nominally significant (p=0.039) but FDR=1.0 after correction. Small co-occurrence count (n=7) limits statistical power.

- source: LITERATURE
  method: LITERATURE_ASSOCIATION
  population: Systematic review/meta-analysis of 4 studies (n=283 Wilson disease patients).
  directionality: UNKNOWN
  statistics:
    metrics:
    - metric_type: PREVALENCE
      metric_value: 0.365
      metric_ci_lower: 0.148
      metric_ci_upper: 0.657
      notes: Pooled prevalence of osteopenia in Wilson disease.
    - metric_type: PREVALENCE
      metric_value: 0.277
      metric_ci_lower: 0.086
      metric_ci_upper: 0.609
      notes: Pooled prevalence of osteoporosis in Wilson disease.
    evidence:
    - reference: PMID:29110062
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;The pooled prevalencerates of osteopenia and osteoporosis in WD patients were 36.5%&#34;
      explanation: Meta-analysis reports substantial pooled prevalence of both osteopenia and osteoporosis in Wilson disease cohorts.

- source: LITERATURE
  method: LITERATURE_ASSOCIATION
  population: Adult-only subgroup from meta-analysis of Wilson disease studies.
  directionality: UNKNOWN
  statistics:
    metrics:
    - metric_type: PREVALENCE
      metric_value: 0.176
      metric_ci_lower: 0.067
      metric_ci_upper: 0.386
      notes: Estimated adult prevalence of osteoporosis in Wilson disease.
    - metric_type: PREVALENCE
      metric_value: 0.0801
      metric_ci_lower: 0.0405
      metric_ci_upper: 0.152
      notes: Estimated adult prevalence of vertebral fracture in Wilson disease.
    evidence:
    - reference: PMID:29110062
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;When meta-analysis was limited only to adults, the estimated prevalence rates of osteopenia, osteoporosis, and vertebral fracture were 50.0% (95%CI: 42.0%-58.0%), 17.6% (95%CI: 6.7%-38.6%) and 8.01% (95%CI: 4.05%-15.2%), respectively.&#34;
      explanation: Adult-only pooled data support clinically relevant osteoporosis and fracture burden in Wilson disease.

- source: LITERATURE
  method: LITERATURE_ASSOCIATION
  population: Pediatric cross-sectional Wilson disease cohort (n=15) with DEXA assessment.
  directionality: UNKNOWN
  statistics:
    metrics:
    - metric_type: PREVALENCE
      metric_value: 0.20
      notes: Osteoporosis prevalence in pediatric Wilson disease cohort.
    evidence:
    - reference: PMID:40950651
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#34;DEXA revealed bone disease in 60%: mild osteopenia (13%), moderate (27%), and osteoporosis (20%).&#34;
      explanation: Pediatric cohort indicates early bone involvement including osteoporosis in Wilson disease.
</pre>
            </details>
            
            <div class="field"><span class="field-label">Source:</span><a href="https://github.com/monarch-initiative/dismech/blob/main/kb/comorbidities/com_Wilsons_Disease__Osteoporosis.yaml" target="_blank">GitHub</a></div>
            
        </div>
    </div>
</body>
</html>